Idorsia

IDIA.SW

Biotechnology · Healthcare

Also trades as: 0RQE.L

Exchange

SIX Swiss Exchange

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Mixed

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

Idorsia is a Swiss biotechnology company that discovers and develops new medicines. It focuses on small-molecule drugs — pills that treat conditions like insomnia, high blood pressure, and other diseases where the body's natural signaling systems are not working properly. The company was founded in 2017 by the former leadership team of Actelion, a well-known Swiss biotech that was sold to Johnson & Johnson.

Idorsia earns revenue mainly by selling its approved drugs, including daridorexant (sold as Quviviq), a sleep disorder treatment approved in the US and Europe, and through licensing deals with larger pharmaceutical partners. The company operates primarily in Europe and North America and is still in an early commercial stage, meaning it spends far more than it earns. Its biggest risk is cash burn — with a deeply negative operating margin, Idorsia depends on raising new capital or securing partnership deals to fund ongoing operations and its broader drug pipeline.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-26.6% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-652.7% YoY

YoY Growth Rate

Earnings declining

Insider Activity

25.8%ownership

↓ Declining

Insider ownership declining — could be dilution or selling

Cash Runway

~10 months

CHF 95M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Cash watch

Idorsia has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

0.0%

Thin — 0.0% gross margin

Profit after running costs

Operating Margin

-67.9%

Losing money on operations — -67.9%

Return on the money invested

ROCE

-73.1%

Weak — -73.1% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-8.0%

Shrinking sales (-8.0% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-70.2%

Burning cash (-70.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

—

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial